Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (19,379,450)	$ (10,639,146)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,049,313	636,093
Amortization of right of use assets	322,854	271,455
Depreciation	4,088	1,427
Forgiveness of PPP loan	(37,772)
Deferred taxes	0	(37,842)
Non-cash interest on redeemable preferred stock	108,591	15,551
Current milestone payable to Patagonia Pharmaceuticals, LLC	1,750,000
Changes in assets and liabilities:
Prepaid research and development	(459,317)	111,993
Other current assets	36,850	(44,941)
Deposits		(13,000)
Accounts payable	397,445	558,300
Accrued expenses	758,977	81,896
Other liabilites	(73,683)
Lease liability	(332,817)	(255,946)
Net cash used in operating activities	(15,854,921)	(9,314,160)
Cash flows from investing activities
Purchases of equipment	(7,084)	(17,804)
Net cash used in investing activities	(7,084)	(17,804)
Cash flows from financing activities
Proceeds from the issuance of common stock and warrants, net of issuance costs	7,989,892	15,791,810
Proceeds from the exercise of common stock warrants	144,000
Net cash provided by financing activities	8,133,892	15,791,810
Net (decrease) increase in cash	(7,728,113)	6,459,846
Cash, beginning of period	16,808,539	10,348,693
Cash, end of period	9,080,426	16,808,539
Non-cash investing and financing activities:
Conversion of Redeemable Series A convertible preferred stock to prefunded common stock warrants	2,163,937
Current milestone payable to Patagonia Pharmaceuticals LLC	1,750,000
Accrued Series A preferred stock dividend		129,992
Cashless exercise of VAR's	$ 60	6
Series A Warrants
Non-cash investing and financing activities:
Cashless exercise of warrants		2,060
Series B Warrants
Non-cash investing and financing activities:
Cashless exercise of warrants		$ 7,468